Skip to main content
Medesis Pharma S.A. logo

Medesis Pharma S.A. — Investor Relations & Filings

Ticker · ALMDP ISIN · FR0010844464 LEI · 969500C15M96P00UR648 PA Manufacturing
Open in API
Filings indexed 118 across all filing types
Latest filing 2025-03-20 Regulatory Filings
Country FR France
Listing PA ALMDP

About Medesis Pharma S.A.

https://www.medesispharma.com/

Medesis Pharma is a clinical-stage pharmaceutical biotechnology company focused on developing treatments for serious diseases using its proprietary AONYS® drug delivery platform. The AONYS® technology is a micro-emulsion designed for buccal (oral) administration, enabling the intracellular delivery of various therapeutic molecules, including metal ions, interfering RNAs, and peptides. A key feature of the platform is its ability to transport active ingredients across the blood-brain barrier, making it a promising approach for neurological disorders. The company's development pipeline addresses diseases with high unmet medical needs, including neurodegenerative conditions like Alzheimer's disease and therapies for individuals exposed to nuclear radiation.

Recent filings

Filing Released Lang Actions
MEDESIS PHARMA : OUVERTURE D'UNE PROCÉDURE DE LIQUIDATION JUDICIAIRE
Regulatory Filings Classification · 95% confidence The document is a formal announcement from MEDESIS PHARMA dated March 20, 2025, stating that the Tribunal de Commerce de Montpellier has opened a 'procédure de liquidation judiciaire' (judicial liquidation proceedings) for the company, following previous safeguard and receivership proceedings. This announcement details a significant legal and financial event concerning the company's operational status and potential shareholder value. This type of critical, non-periodic legal/financial update that doesn't fit standard reporting (10-K, ER, IR) or specific transaction types (DIV, CAP) is best classified as a general Regulatory Filing (RNS) or potentially a Legal Proceedings Report (LTR). Given that it announces the definitive closure/liquidation order by a court, which is a major regulatory event impacting the company's existence, RNS is the most appropriate general regulatory fallback, although LTR is also plausible. Since it is a direct announcement of a court decision affecting the company's status, RNS (Regulatory Filings) serves as the best fit among the provided options for a critical, non-standard regulatory event notice.
2025-03-20 French
MEDESIS PHARMA A FINALISÉ L’ÉTUDE CLINIQUE POUR LE TRAITEMENT DE LA MALADIE D’ALZHEIMER AVEC LE NANOLITHIUM
Earnings Release Classification · 95% confidence The document is a press release ("COMMUNIQUÉ DE PRESSE") from MEDESIS PHARMA announcing the finalization of a clinical study for Alzheimer's treatment using NanoLithium. It details interim results (Phase 2a), patient safety, and future expectations (final results expected Q1 2025). This type of announcement, focusing on the completion of a study phase and preliminary efficacy/safety data, is characteristic of an Earnings Release (ER) or a general corporate update. Since it is a formal announcement of key results rather than a comprehensive periodic report (like 10-K or IR), and it is not a transcript (CT) or a presentation (IP), the most fitting category is Earnings Release (ER), which covers initial announcements of periodical financial/operational results. Although the content is clinical trial progress, in the context of financial filings, major operational milestones like this are often released via ER mechanisms or RNS. Given the structure as a press release detailing key operational achievements and financial outlook context (fundraising mentioned), ER is a strong fit, though RNS is a possibility if it were purely regulatory. Since it provides specific, time-sensitive operational results, ER is preferred over the general RNS fallback. Q4 2024
2024-11-20 French
MEDESIS PHARMA HAS COMPLETED ITS CLINICAL STUDY FOR THE TREATMENT OF ALZHEIMER'S DISEASE WITH NANOLITHIUM
Regulatory Filings Classification · 95% confidence The document is a 'PRESS RELEASE' announcing the completion of a clinical study for a drug candidate (NanoLithium) for Alzheimer's disease. It details interim results (Phase 2a), patient tolerance, and future expectations for final results (Q1 2025). This type of announcement, focusing on clinical trial progress and scientific findings, is characteristic of an update intended for investors and the public regarding the company's core product development pipeline. It is not a formal regulatory filing like a 10-K, a comprehensive quarterly report (IR), or a simple earnings release (ER). Since it is a detailed update on drug development and scientific progress, it fits best under Investor Presentation (IP) or potentially Regulatory Filings (RNS) if no better fit exists. Given the detailed scientific and clinical data presentation aimed at informing investors about the drug's status, 'Investor Presentation' (IP) is the most appropriate classification, as these press releases often serve as the primary communication vehicle for such updates, similar to what might be presented in an IP deck. However, looking closely at the definitions, 'Investor Presentation' (IP) is defined as a 'Detailed presentation for investors focusing on financials, strategy, and market position.' While this document focuses on strategy/pipeline, it is structured as a press release announcing study completion, not a formal presentation deck. Since it is a specific announcement about clinical trial progress and scientific data, and not a general regulatory filing (RNS) or a formal financial report, it is closest to the type of material shared in an Investor Presentation, but it is fundamentally a press release announcing scientific progress. In the absence of a specific 'Clinical Trial Update' category, and given that it is a detailed communication aimed at investors about the pipeline, IP is the strongest fit among the provided options, although RNS is a possibility if the focus is purely on the announcement format rather than the content type. Revisiting the options: It is not an ER (only clinical data), not an IR (not a full financial report), not a CT (not a transcript). It is a detailed update on the product pipeline. I will classify it as Investor Presentation (IP) because the content is highly focused on the development status of a key asset, which is a core component of investor communication materials.
2024-11-20 English
MEDESIS PHARMA : CONVERSION DE LA PROCÉDURE DE SAUVEGARDE EN REDRESSEMENT JUDICIAIRE
Legal Proceedings Report Classification · 99% confidence The document is a press release ("COMMUNIQUÉ DE PRESSE") announcing a significant legal and financial event: the conversion of a 'sauvegarde' (safeguard procedure) into 'redressement judiciaire' (judicial reorganization) by the Commercial Court of Montpellier. This relates directly to the company's financial distress and restructuring efforts. This type of announcement, detailing legal proceedings impacting the company's structure and operations, fits best under the 'Legal Proceedings Report' (LTR) category, as it is a formal update on a significant legal matter affecting the company's viability. It is not a standard earnings release (ER), an annual report (10-K), or a general financing update (CAP), but a specific report on a court-mandated restructuring process.
2024-11-14 French
MEDESIS PHARMA : Rapport Financier Semestriel 2024
Interim / Quarterly Report Classification · 100% confidence The document is titled 'Rapport Financier Semestriel 2024' (Semi-annual Financial Report 2024) and contains detailed financial statements including the balance sheet (actif/passif) and income statement for the period from 01/01/2024 to 30/06/2024. It provides substantive financial data rather than just an announcement or certification. Therefore, it is classified as an Interim/Quarterly Report. H1 2024
2024-11-12 French
MEDESIS PHARMA : Activités & résultats du 1er semestre 2024
Earnings Release Classification · 99% confidence The document text contains a table with financial figures comparing '30 juin 2024 (6 mois)' and '30 juin 2023 (6 mois)', indicating a report covering the first half of the year. The text explicitly mentions: 'Les comptes sociaux du 1ª semestre 2024, non audités, établis conformément aux normes comptables françaises, ont été arrêtés par le Directoire...'. Furthermore, the final section is titled 'Mise à disposition du rapport financier semestriel 2024' and states that the 'Rapport Financier Semestriel 2024 est mis à disposition du public et déposé auprès de l'Autorité des Marchés Financiers ce jour'. This clearly identifies the document as a comprehensive financial report for an interim period (six months), matching the definition of an Interim / Quarterly Report (IR). Although it is an announcement of the report's availability, the core content provided is the financial data itself, making IR a stronger classification than RPA, especially given the detailed financial tables. H1 2024
2024-11-12 French

Browse filings by year

5 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.